Prevalence and characteristics of polycystic ovarian syndrome in patients with bipolar disorder

J Affect Disord. 2023 Nov 1:340:387-395. doi: 10.1016/j.jad.2023.08.007. Epub 2023 Aug 4.

Abstract

Background: Bipolar disorder (BD) is frequently accompanied by endocrine disturbances. We compared the prevalence of polycystic ovary syndrome (PCOS) and related reproductive disorders between drug-naïve BD patients and matched healthy controls (HCs) and between drug-naïve BD patients and BD patients with long-term medication, as well as the clinical metabolic correlates among BD patients.

Methods: 72 drug-naïve BD patients, 98 HCs, and 72 BD patients with long-term medication were recruited in the study. Menstruation was recorded, reproductive hormone levels and metabolic indicators were measured, and a pelvic ultrasound examination was performed via transvaginal sensor for each participant. PCOS was defined using the Rotterdam criteria.

Results: After controlling for demographic variables, drug-naïve BD patients presented higher rates of PCOS than the HCs (OR: 3.02, 95 % CI: 1.09-8.36). Regression analysis showed that long-term treatment with valproate (OR: 3.89, 95 % CI: 1.13-13.37), age (OR: 0.37, 95 % CI: 0.14-0.95), and insulin resistance index (OR: 1.73, 95 % CI: 1.10-12.71) were correlated with PCOS in BD patients.

Conclusions: Drug-naïve BD patients are susceptible to developing PCOS, and valproate is correlated with increased occurrence and development of PCOS. Therefore, PCOS in BD patients, especially those who use valproate, needs to be investigated and monitored closely by medical personnel.

Keywords: Bipolar disorder (BD); Comparative study; Drug-related side effects; Pharmacology; Polycystic ovary syndrome (PCOS); Reproductive disorders.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bipolar Disorder* / complications
  • Bipolar Disorder* / epidemiology
  • Female
  • Humans
  • Insulin Resistance*
  • Polycystic Ovary Syndrome* / complications
  • Polycystic Ovary Syndrome* / epidemiology
  • Prevalence
  • Valproic Acid

Substances

  • Valproic Acid